BTIG initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $11 price target The firm says Foghorn is a clinical-stage biopharmaceutical company developing novel inhibitors and degraders for various oncology indications. BTIG views the shares undervalued into the company’s Phase 1 data in 2026. The share setup is favorable into the readout for FHD-909, a “potent and selective” inhibitor of SMARCA2 currently in Phase 1a dose escalation for solid tumors, BTIG contends.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Appoints Interim CFO Jeff Sacher
- Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast
- Foghorn Therapeutics initiated with a Buy at Stifel
- Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
- Foghorn Therapeutics Unveils Strategic Advancements with Lilly